NCT02368665 - A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions

Essential Hypertension

Interventions

DRUG

Amlodipine 5mg

\- Daily oral administration for 8 weeks

DRUG

Amlodipine 5mg, Candesartan cilexetil 16mg

\- Daily oral administration Amlodipine 5mg for 8 weeks

DRUG

Amlodipine 10mg, Candesartan cilexetil 16mg

\- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks

Trial Locations (19)

Hallym University Sungsim Hospital, Anyang-si

Inje University Busan Baik Hospital, Busan

Inje University Haeundae Baik Hospital, Busan

Yeungnam University Medical Center, Daegu

Chonnam National University Hospital, Gwangju

Inje University Ilsan Baik Hospital, Ilsan

Inha University Hospital, Incheon

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Ewha Womans University Mokdong Hospital, Seoul

Gangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

Korea University Guro Hospital, Seoul

Seoul Medical Center, Seoul

Seoul St. Mary's Hospital Catholic University, Seoul

Soonchunhyang University Hospital, Seoul

Yonsei University Severance Hospital, Seoul

Ajou University Hospital, Suwon

Wonju Severance Christian Hospital, Wŏnju